UK endows £250m to life sciences
Enlarge image


UK endows £250m to life sciences

25.05.2012 - With the aim to maintain its status one of the global leading life sciences nations, the UK has set up a large funding initiative.

London – Minister for Universities and Science, David Willetts, announced that £250M has been allocated for the first phase of several five year strategic investment programmes. This includes 26 strategic science programmes and 14 key national research capabilities, to be delivered by eight of the UK's world-leading bioscience research institutes and their university partners. The process will be led by Britain's Biotechnology and Biological Sciences Research Council (BBSRC). 

Commenting on the funding, Willetts said: "This investment will sustain excellent science at some of the UK's leading institutes and universities. This will drive growth, support highly skilled jobs and keep the UK at the very forefront of bioscience, with benefits ranging from healthcare to energy and global food security." The plan is thought to help the UK to meet challenges such as sustainably feeding the growing world population, finding alternatives to dwindling fossil fuels and supporting an ageing society to remain healthy for longer.  

The Minister made the announcement in a speech during a visit at the Babraham Research Campus. The campus, a BBSRC National Research and Innovation Campus, is one of the privileged institutes and will receive £37M. Others are the Institute of Biological, Environmental and Rural Sciences, Aberystwyth University (£13M), the Genome Analysis Centre in Norwich (£19M), the Roslin Institute at the University of Edinburgh (£23M), the Institute for Animal Health in Pirbright (£38M), the Institute of Food Research in Norwich (£29M), the John Innes Centre in Norwich (£42M) and the Rothamsted Research in Harpenden (£41M).

The initiative complements a funding programme aimed to boost translational medicine, that was announced in April.


01.12.2015 Almirall is strengthening its dermatology focus with the takeover of Poli Group. Part of the deal are the group’s two pharma companies, German Taurus Pharma GmbH and Swiss Polichem S.A., and Italian Polichem S.r.l., which produces plastics additives.


26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • BIOFRONTERA (D)1.99 EUR6.99%
  • EPIGENOMICS (D)2.80 EUR5.66%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • EVOCUTIS (UK)0.11 GBP-8.33%
  • SARTORIUS (D)246.25 EUR-7.08%


  • PLETHORA (UK)5.50 GBP100.0%
  • GENMAB (DK)910.00 DKK33.8%


  • EPIGENOMICS (D)2.80 EUR-43.4%
  • EVOCUTIS (UK)0.11 GBP-26.7%


  • KARO BIO (S)37.60 SEK5349.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)47.21 EUR263.2%


  • BIOTEST (D)15.71 EUR-80.7%
  • NEOVACS (F)0.78 EUR-76.6%

No liability assumed, Date: 01.12.2015